Biopharmaceuticals, Neurology, and Rare Disease Research by Biohaven

  • Ashutosh Sureka
  • 18 hours ago
Biohaven stock falls to $14.80 with volatility persisting after clinical trial announcement
Biohaven said investigators are excited about BHV-1300 because of its innovation and potential to advance Graves’ disease treatment.The company described BHV-1300’s approach as targeted and ...
  • Sholanke Dele
  • 09.06.2026
Biohaven stock rises above key averages amid pipeline update at industry event
Biohaven announced that its Chief Translational Officer will speak at the Goldman Sachs Annual Global Healthcare Conference.The presenter will share insights on Biohaven’s pipeline developments. ...
  • Ashutosh Sureka
  • 04.06.2026
Biohaven stock rises 4.84% as leadership details pipeline progress at R&D Day event
Biohaven held its annual Research & Development Day to update investors and industry experts on its latest pipeline progress.The company presented new information in areas including immunology, ...